Metraipolis › archive › dc_fc2393eef420

Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling — Europe PMC PMID:42455066

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42455066
DOI
10.1128/aac.01541-25
License (as archived)
solo-consultazione
Archived
2026-10-08T06:57:22.577Z
SHA-256 of the archived text
55a42199b61f6fcc3cf8fb84c94f12f06098a80bb9f12a05534b9bb7bed891be
Stable URL of this page
https://metraipolis.com/documento/dc_fc2393eef420

How to cite

Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling — Europe PMC PMID:42455066 — Europe PMC (en), https://europepmc.org/article/MED/42455066 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fc2393eef420 (Metraipolis archive dc_fc2393eef420, sha256 55a42199b61f6fcc3cf8fb84c94f12f06098a80bb9f12a05534b9bb7bed891be)
BibTeX
@misc{dcfc2393eef420,
  title = {Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling — Europe PMC PMID:42455066},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42455066},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fc2393eef420; sha256 55a42199b61f6fcc3cf8fb84c94f12f06098a80bb9f12a05534b9bb7bed891be},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42455066. Agents can read the archived copy with the MCP tool read_document.